• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Harrow announces licensing agreement with Apotex to market 5 ophthalmic products in Canada


Products under the terms of the agreement include VERKAZIA, Cationorm PLUS, VEVYE, IHEEZO, and ZERVIATE.

(Image Credit: AdobeStock)

(Image Credit: AdobeStock)

Harrow Inc and Apotex Inc have entered an “exclusive out-licensing agreement” in which Apotex will will market and distribute VERKAZIA and Cationorm PLUS in the Canadian market, and concurrently, pursue market approval in Canada for VEVYE, IHEEZO, and ZERVIATE.1

“We are pleased to enter the Canadian market through this partnership with Apotex, which has a proven track record of success serving Canadian eyecare professionals and their patients,” said Mark L Baum, Chairman and Chief Executive Officer of Harrow in a press release1 from the company. “This exclusive agreement fulfills our commitment to access and availability of these five important ophthalmic pharmaceutical products, and we look forward to working closely with our partners at Apotex over the coming years as they seek approval for VEVYE, IHEEZO and ZERVIATE in the Canadian market.”

Products involved in the deal include:1

  • cyclosporine ophthalmic emulsion 0.1%, (VERKAZIA) a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis (VKC) in children.
  • Cationorm PLUS, an OTC, preservative-free emulsion for the treatment of dry eye symptoms and the treatment of signs and symptoms of ocular allergy.
  • cyclosporine ophthalmic solution 0.1% (VEVYE) a novel water-free vehicle (perfluorobutylpentane) based on semifluorinated alkanes, indicated to treat the signs and symptoms of dry eye disease.
  • chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO), a single-use, low-viscosity gel indicated for ocular surface anesthesia.
  • cetirizine ophthalmic solution 0.24% (ZERVIATE), a histamine-1 (H1) receptor antagonist indicated for the treatment of ocular itching associated with allergic conjunctivitis.

“Adding these products strengthens our therapeutic line and provides Canadian patients with valuable new treatment options,” said Mike Woolcock, Senior Vice President, Biosimilars & Specialty in the release. “We look forward to collaborating with Harrow to expand this line with VEVYE, IHEEZO, and ZERVIATE upon receiving market approval to improve the overall patient quality of life in this category.”

  1. Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products. Press release; February 15, 2024. Accessed February 16, 2024. https://www.businesswire.com/news/home/20240215859659/en
Related Videos
Video 3 - "Approaching Asymptomatic Cases with Risk Factors"
Video 2 - "Do Dry Eye Diagnostics Change the Management of Dry Eye?"
Andrew Pucker, OD, PhD
Video 1 - "Challenging the Definition of Dry Eye- Interpreting Diagnostic Tests"
© 2024 MJH Life Sciences

All rights reserved.